HTLV-I/II seroprevalence in 55 Brazilian patients with idiopathic uveitis

Turning a blind eye: HTLV-1-associated uveitis in Indigenous adults from Central Australia

PURPOSE

We describe the first two cases of HTLV-1 associated uveitis to be associated with HTLV-1c subtype infection.

METHODS

Case report.

RESULTS

Uveitis was demonstrated in two Indigenous Australian men, both of whom had high HTLV-1c proviral loads in peripheral blood. Visual outcomes were poor in each case.

CONCLUSION

Clinicians should be aware of HTLV-1c infection as a cause of uveitis in Australia, and HTLV-1 serology should be included in the basic uveitis work-up in HTLV-1-endemic areas.

Inflammatory manifestations of HTLV-1 and their therapeutic options

Human T lymphotropic virus type 1 (HTLV-1) is one of the most intriguing retroviruses infecting humans. Most commonly, infection remains undetected, since it does not cause obvious harm, yet in 4-9% of patients, this infection can be devastating, causing adult T-cell leukemia/lymphoma and/or HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). This review concentrates on all inflammatory aspects of HTLV-1 infection: HAM/TSP, HTLV-1 associated uveitis, HTLV-1 associated conjunctivitis, sicca syndrome and interstitial keratitis, HTLV-1 associated Sjögren's syndrome, Hashimoto's thyroiditis and Graves' disease, HTLV-1 associated pulmonary disease, infective dermatitis associated with HTLV-1, HTLV-1 associated inflammatory myositis and HTLV-1 associated arthritis. With the exception of HAM/TSP treatment, studies of these conditions are sparse and even for HAM/TSP, the level of evidence is limited. While control or elimination of infection remains a goal, most therapy beyond symptomatic management is directed at the immune response to HTLV-1.

Global epidemiology of HTLV-I infection and associated diseases

Epidemiologic aspects of human T-lymphotropic virus type I (HTLV-I) infection have been thoroughly studied over the course of approximately 25 years since its first description. The geographic distribution of the virus has been defined, with Japan, Africa, Caribbean islands and South America emerging as the areas of highest prevalence. The reasons for HTLV-I clustering, such as the high ubiquity in southwestern Japan but low prevalence in neighboring regions of Korea, China and eastern Russia are still unknown. The major modes of transmission are well understood, although better quantitative data on the incidence of transmission, and on promoting/inhibiting factors, are needed. Epidemiologic proof has been obtained for HTLV-I's causative role in major disease associations: adult T-cell leukemia (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-associated uveitis and infective dermatitis. However, more and better studies are needed for other apparent disease outcomes such as rheumatologic, psychiatric and infectious diseases. Since curative treatment of ATL and HAM/TSP is lacking and a vaccine is unavailable, the social and financial cost for the individual, his/her family and the health system is immense. For this reason, public health interventions aimed at counseling and educating high-risk individuals and populations are of paramount importance.

Os vírus linfotrópicos de células T humanos (HTLV) na última década (1990-2000): aspectos epidemiológicos

Vinte anos após o isolamento do vírus linfotrópico humano tipo I, muitos aspectos epidemiológicos, patogênicos e filogenéticos já estão esclarecidos. Sabe-se que em regiões endêmicas a prevalência aumenta com a idade e é maior no sexo feminino. Três patologias estão claramente relacionadas a ele: paraparesia espástica tropical / mielopatia associada ao HTLV, leucemia de células T do adulto e uveíte. Os modos de infecção, semelhantes aos dos outros retrovírus, são: transfusão de sangue, relações sexuais não protegidas, transplacentária e durante o aleitamento materno. A história natural das doenças relacionadas ao HTLV-I ainda não está bem estabelecida. O risco de portadores da infecção desenvolverem patologias depende de mais estudos de incidência para serem corretamente estimados. Menos se conhece sobre o HTLV-II. A despeito do alto grau de homologia entre os dois tipos, os vírus interagem de forma bem diversa com os infectados, não havendo uma associação clara de doença com o HTLV-II. Relatos recentes têm apontado sua participação em casos de mielopatia crônica semelhante à TSP/HAM. As implicações incertas do prognóstico para pessoas infectadas pelo vírus linfotrópico humano (HTLV-I/II) e suas formas de transmissão constituem um problema de saúde pública, principalmente em áreas consideradas endêmicas para esse vírus.